ELTP is swelling, the question is when the dam will give.
With a handful of haters and a swarm of newbie's to the scene, the message boards on various sites are lacking the same confidence as three or four years ago, but there is plenty of technical aspects that continues to draw enough attention for better or worse.
Today's conference call isn't going to do enough to stimulate a buying frenzy, with a disappointing $2.6 million quarter the best that can be done is to notice this is an upward trend month over month. Of course it's not when you look at the year over year numbers, so it looks like the sticks will be pushed forward to next quarter if that's what is most important on your mind.
Now if the FDA would just relax and just grant ELTP their prize piece of their puzzle, there could be a modest eruption. In the meanwhile, their pieces continue to approved, however slowly. It's sometimes painful, and Nasrat has put a lot of his supporters on the defensive. He needs to get some things going his way.
With a handful of haters and a swarm of newbie's to the scene, the message boards on various sites are lacking the same confidence as three or four years ago, but there is plenty of technical aspects that continues to draw enough attention for better or worse.
Today's conference call isn't going to do enough to stimulate a buying frenzy, with a disappointing $2.6 million quarter the best that can be done is to notice this is an upward trend month over month. Of course it's not when you look at the year over year numbers, so it looks like the sticks will be pushed forward to next quarter if that's what is most important on your mind.
Now if the FDA would just relax and just grant ELTP their prize piece of their puzzle, there could be a modest eruption. In the meanwhile, their pieces continue to approved, however slowly. It's sometimes painful, and Nasrat has put a lot of his supporters on the defensive. He needs to get some things going his way.
